Literature DB >> 22275373

Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.

Shaoyong Chen1, Sarah Gulla, Changmeng Cai, Steven P Balk.   

Abstract

Our previous findings indicated that androgen receptor (AR) phosphorylation at serine 81 is stimulated by the mitotic cyclin-dependent kinase 1 (CDK1). In this report, we extended our previous study and confirmed that Ser-81 phosphorylation increases during mitosis, coincident with CDK1 activation. We further showed blocking cell cycle at G(1) or S phase did not disrupt androgen-induced Ser-81 phosphorylation and AR-dependent transcription, consistent with a recent report that AR was phosphorylated at Ser-81 and activated by the transcriptional CDK9. To assess the function of Ser-81 phosphorylation in prostate cancer (PCa) cells expressing endogenous AR, we developed a ligand switch strategy using a ligand-binding domain mutation (W741C) that renders AR responsive to the antagonist bicalutamide. An S81A/W741C double mutant AR stably expressed in PCa cells failed to transactivate the endogenous AR-regulated PSA or TMPRSS2 genes. ChIP showed that the S81A mutation prevented ligand-induced AR recruitment to these genes, and cellular fractionation revealed that the S81A mutation globally abrogated chromatin binding. Conversely, the AR fraction rapidly recruited to chromatin after androgen stimulation was highly enriched for Ser-81 phosphorylation. Finally, inhibition of CDK1 and CDK9 decreased AR Ser-81 phosphorylation, chromatin binding, and transcriptional activity. These findings indicate that Ser-81 phosphorylation by CDK9 stabilizes AR chromatin binding for transcription and suggest that CDK1-mediated Ser-81 phosphorylation during mitosis provides a pool of Ser-81 phosphorylation AR that can be readily recruited to chromatin for gene reactivation and may enhance AR activity in PCa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275373      PMCID: PMC3318700          DOI: 10.1074/jbc.M111.325290

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions.

Authors:  Xianzhuo Zeng; Shuai Chen; Haojie Huang
Journal:  Cell Cycle       Date:  2011-02-15       Impact factor: 4.534

Review 2.  CDK8: a positive regulator of transcription.

Authors:  Matthew D Galbraith; Aaron J Donner; Joaquín M Espinosa
Journal:  Transcription       Date:  2010 Jul-Aug

3.  Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites.

Authors:  G Jenster; P E de Ruiter; H A van der Korput; G G Kuiper; J Trapman; A O Brinkmann
Journal:  Biochemistry       Date:  1994-11-29       Impact factor: 3.162

Review 4.  Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

Authors:  Changmeng Cai; Steven P Balk
Journal:  Endocr Relat Cancer       Date:  2011-08-30       Impact factor: 5.678

5.  Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.

Authors:  Zhigang Kang; Asta Pirskanen; Olli A Jänne; Jorma J Palvimo
Journal:  J Biol Chem       Date:  2002-10-09       Impact factor: 5.157

6.  FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.

Authors:  B He; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1.

Authors:  Shaoyong Chen; Cristina T Kesler; Bryce M Paschal; Steven P Balk
Journal:  J Biol Chem       Date:  2009-07-21       Impact factor: 5.157

8.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

Review 9.  The contribution of different androgen receptor domains to receptor dimerization and signaling.

Authors:  Margaret M Centenera; Jonathan M Harris; Wayne D Tilley; Lisa M Butler
Journal:  Mol Endocrinol       Date:  2008-07-10

10.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

View more
  49 in total

1.  Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7.

Authors:  Friedemann Zengerling; Anca Azoitei; Alexander Herweg; Florian Jentzmik; Marcus V Cronauer
Journal:  World J Urol       Date:  2015-08-29       Impact factor: 4.226

2.  Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer.

Authors:  Joshua W Russo; Xiaming Liu; Huihui Ye; Carla Calagua; Sen Chen; Olga Voznesensky; James Condulis; Fen Ma; Mary-Ellen Taplin; David J Einstein; Steven P Balk; Shaoyong Chen
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

Review 3.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

4.  CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.

Authors:  Reyaz Ur Rasool; Ramakrishnan Natesan; Qu Deng; Shweta Aras; Priti Lal; Samuel Sander Effron; Erick Mitchell-Velasquez; Jessica M Posimo; Shannon Carskadon; Sylvan C Baca; Mark M Pomerantz; Javed Siddiqui; Lauren E Schwartz; Daniel J Lee; Nallasivam Palanisamy; Goutham Narla; Robert B Den; Matthew L Freedman; Donita C Brady; Irfan A Asangani
Journal:  Cancer Discov       Date:  2019-08-29       Impact factor: 39.397

Review 5.  Molecular pathogenesis and progression of prostate cancer.

Authors:  Randy Schrecengost; Karen E Knudsen
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

Review 6.  Phosphorylation: a fundamental regulator of steroid receptor action.

Authors:  Lindsey S Treviño; Nancy L Weigel
Journal:  Trends Endocrinol Metab       Date:  2013-07-06       Impact factor: 12.015

7.  Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.

Authors:  Zhuo Yu; Hai Feng; Yunhui Zhuo; Man Li; Xiaojun Zhu; Lingying Huang; Xin Zhang; Zhenhua Zhou; Chao Zheng; Yun Jiang; Fan Le; Dae-Yeul Yu; Alfred Szelok Cheng; Xuehua Sun; Yueqiu Gao
Journal:  Cell Oncol (Dordr)       Date:  2020-07-04       Impact factor: 6.730

8.  COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer.

Authors:  Ken-Ichi Takayama; Takashi Suzuki; Tetsuya Fujimura; Satoru Takahashi; Satoshi Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

9.  Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells.

Authors:  Aya Misawa; Ken-Ichi Takayama; Tomohiko Urano; Satoshi Inoue
Journal:  J Biol Chem       Date:  2016-06-24       Impact factor: 5.157

Review 10.  Androgen receptor phosphorylation: biological context and functional consequences.

Authors:  Yulia Koryakina; Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-01-14       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.